Medscape InDiscussion: MASLD

About Medscape InDiscussion: MASLD

Listen to Medscape InDiscussion: MASLD, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Publisher

Medscape

Category

health & fitness · science

Language

en

Explicit

No

First episode

25 Jun 2026

Latest episode

29 Oct 2026

Latest episodes

6 episodes in the feed.

1. 

   29 Oct 2026

   Are We Missing Heart Risk in MASLD?

   Drs Lisa VanWagner and Kathleen Corey examine how MASLD should shape cardiovascular risk assessment, statin use, and treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep6-2026a1000aay (https://www.medscape.com/ca8/p04/podcast-masld-s1-ep6-2026a1000aay). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5 (https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5) Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/41124780/ (https://pubmed.ncbi.nlm.nih.gov/41124780/) FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis (https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis) Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease https://pubmed.ncbi.nlm.nih.gov/32707340/ (https://pubmed.ncbi.nlm.nih.gov/32707340/) Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34555346/ (https://pubmed.ncbi.nlm.nih.gov/34555346/) Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807924/ (https://pubmed.ncbi.nlm.nih.gov/37807924/) 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/41824552/ (https://pubmed.ncbi.nlm.nih.gov/41824552/) CVD Risk Estimator Plus https://tools.acc.org/cvd-risk-estimator-plus/#!/calculate/estimate/ (https://tools.acc.org/cvd-risk-estimator-plus/#!/calculate/estimate/) Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review https://pubmed.ncbi.nlm.nih.gov/34613362/ (https://pubmed.ncbi.nlm.nih.gov/34613362/) Risk-Associated and Clinically Informative Biomarkers for Cardiovascular Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41624044/ (https://pubmed.ncbi.nlm.nih.gov/41624044/) Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein https://pubmed.ncbi.nlm.nih.gov/18997196/ (https://pubmed.ncbi.nlm.nih.gov/18997196/) Statin Liver Safety in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Metanalysis https://pubmed.ncbi.nlm.nih.gov/34133035/ (https://pubmed.ncbi.nlm.nih.gov/34133035/) Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance https://pubmed.ncbi.nlm.nih.gov/39422487/ (https://pubmed.ncbi.nlm.nih.gov/39422487/) Effect of Non-Statin Lipid-Lowering Therapy on Hepatic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/41048606/ (https://pubmed.ncbi.nlm.nih.gov/41048606/) The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective https://pubmed.ncbi.nlm.nih.gov/24084292/ (https://pubmed.ncbi.nlm.nih.gov/24084292/) The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/) Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future Directions https://pubmed.ncbi.nlm.nih.gov/39493945/ (https://pubmed.ncbi.nlm.nih.gov/39493945/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.

2. 

   24 Sept 2026

   Beyond Lifestyle: A Practical Guide to Liver-Directed Therapy for MASH

   Dr Mazen Noureddin explains how PCPs can identify MASH patients with fibrosis who may benefit from liver-directed therapy, while maintaining lifestyle and metabolic care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep5-2026a1000aax (https://www.medscape.com/ca8/p04/podcast-masld-s1-ep5-2026a1000aax). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 (https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1) Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview (https://emedicine.medscape.com/article/175472-overview) Hepatic Thyroid Hormone Receptor-β Signalling: Mechanisms and Recent Advancements in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/39658733/ (https://pubmed.ncbi.nlm.nih.gov/39658733/) Cardiovascular-Kidney-Metabolic (CKM) Syndrome https://emedicine.medscape.com/article/165124-overview (https://emedicine.medscape.com/article/165124-overview) Diagnostic Performance of Circulating Biomarkers for Non-Alcoholic Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/37679433/ (https://pubmed.ncbi.nlm.nih.gov/37679433/) The Role of Fibroscan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/) Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/37632072/ (https://pubmed.ncbi.nlm.nih.gov/37632072/) FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis (https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis) MELD 3.0 in Advanced Chronic Liver Disease https://pubmed.ncbi.nlm.nih.gov/37751367/ (https://pubmed.ncbi.nlm.nih.gov/37751367/) The Enhanced Liver Fibrosis (ELF) Test in Diagnosis and Management of Liver Fibrosis https://pubmed.ncbi.nlm.nih.gov/30526098/ (https://pubmed.ncbi.nlm.nih.gov/30526098/) Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial https://pubmed.ncbi.nlm.nih.gov/41127972/ (https://pubmed.ncbi.nlm.nih.gov/41127972/) Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance https://pubmed.ncbi.nlm.nih.gov/39422487/ (https://pubmed.ncbi.nlm.nih.gov/39422487/) Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis https://pubmed.ncbi.nlm.nih.gov/39038768/ (https://pubmed.ncbi.nlm.nih.gov/39038768/) Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations https://pubmed.ncbi.nlm.nih.gov/42483637/ (https://pubmed.ncbi.nlm.nih.gov/42483637/) FDA Accelerated Approval Program https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program (https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program) A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH https://pubmed.ncbi.nlm.nih.gov/34670042/ (https://pubmed.ncbi.nlm.nih.gov/34670042/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.

3. 

   27 Aug 2026

   How Early Is Early Enough to Reverse MASLD?

   Drs VanWagner and Chen discuss whether fatty liver is reversible, weight-loss targets, diet quality, exercise, and where GLP-1s and bariatric surgery fit into MASLD treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep4-2026a1000aaw (https://www.medscape.com/ca8/p04/podcast-masld-s1-ep4-2026a1000aaw). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 (https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1) Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview (https://emedicine.medscape.com/article/175472-overview) Two-Year Mediterranean Diet Intervention Improves Hepatic Health in MASLD Patients https://pubmed.ncbi.nlm.nih.gov/40428516/ (https://pubmed.ncbi.nlm.nih.gov/40428516/) An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans https://pubmed.ncbi.nlm.nih.gov/29456073/ (https://pubmed.ncbi.nlm.nih.gov/29456073/) Intermittent Fasting Improves Hepatic End Points in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/37534936/ (https://pubmed.ncbi.nlm.nih.gov/37534936/) Effect of 5:2 Intermittent Fasting Diet Versus Daily Calorie Restriction Eating on Metabolic-Associated Fatty Liver Disease — A Randomized Controlled Trial https://pubmed.ncbi.nlm.nih.gov/39229586/ (https://pubmed.ncbi.nlm.nih.gov/39229586/) Physical Activity Compared to Adiposity and Risk of Liver-Related Mortality: Results From Two Prospective, Nationwide Cohorts https://pubmed.ncbi.nlm.nih.gov/31954204/ (https://pubmed.ncbi.nlm.nih.gov/31954204/) Adult Activity: An Overview https://www.cdc.gov/physical-activity-basics/guidelines/adults.html (https://www.cdc.gov/physical-activity-basics/guidelines/adults.html) Positive Effects of Exercise Intervention Without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34579012/ (https://pubmed.ncbi.nlm.nih.gov/34579012/) Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/39896971/ (https://pubmed.ncbi.nlm.nih.gov/39896971/) Bariatric Surgery Reduces Long-Term Mortality in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis https://pubmed.ncbi.nlm.nih.gov/39541951/ (https://pubmed.ncbi.nlm.nih.gov/39541951/) Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications https://pubmed.ncbi.nlm.nih.gov/41153720/ (https://pubmed.ncbi.nlm.nih.gov/41153720/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.

4. 

   23 Jul 2026

   Incidental Fatty Liver on Imaging: What Should You Do Next?

   When fatty liver appears incidentally on imaging, "just lose weight" isn't enough. Dr Brandman explains how to use FIB-4, FibroScan, and ELF to triage who needs referral and who doesn't. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep3-2026a1000aav. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 (https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1) Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview (https://emedicine.medscape.com/article/175472-overview) MetALD: Clinical Aspects, Pathophysiology and Treatment https://pubmed.ncbi.nlm.nih.gov/39897615/ (https://pubmed.ncbi.nlm.nih.gov/39897615/) Cirrhosis https://emedicine.medscape.com/article/185856-overview (https://emedicine.medscape.com/article/185856-overview) The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/) Magnetic Resonance Elastography of the Liver: Everything You Need to Know to Get Started https://pmc.ncbi.nlm.nih.gov/articles/PMC9538666/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC9538666/) A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/39131248/ (https://pubmed.ncbi.nlm.nih.gov/39131248/) Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis https://pmc.ncbi.nlm.nih.gov/articles/PMC11240480/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC11240480/) Viral Hepatitis https://emedicine.medscape.com/article/775507-overview (https://emedicine.medscape.com/article/775507-overview) Autoimmune Hepatitis (AIH) https://emedicine.medscape.com/article/172356-overview (https://emedicine.medscape.com/article/172356-overview) FibroSURE as a Noninvasive Marker of Liver Fibrosis and Inflammation in Chronic Hepatitis B https://pubmed.ncbi.nlm.nih.gov/24990385/ (https://pubmed.ncbi.nlm.nih.gov/24990385/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.

5. 

   25 Jun 2026

   Is Alcohol the Missing Piece in Your MASLD Workup?

   Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep2-2026a1000aau (https://www.medscape.com/ca8/p04/podcast-masld-s1-ep2-2026a1000aau). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 (https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1) Is Moderate Alcohol Use in Nonalcoholic Fatty Liver Disease Good or Bad? A Critical Review https://pubmed.ncbi.nlm.nih.gov/28100008/ (https://pubmed.ncbi.nlm.nih.gov/28100008/) Practical Guide, Challenges, and Pitfalls in Liver Fibrosis Staging https://pubmed.ncbi.nlm.nih.gov/37536882/ (https://pubmed.ncbi.nlm.nih.gov/37536882/) Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/29378307/ (https://pubmed.ncbi.nlm.nih.gov/29378307/) A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature https://pubmed.ncbi.nlm.nih.gov/37363821/ (https://pubmed.ncbi.nlm.nih.gov/37363821/) Phosphatidylethanol in Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/40759197/ (https://pubmed.ncbi.nlm.nih.gov/40759197/) Phosphatidylethanol and Self-Reported Alcohol Intake to Subclassify Individuals at Risk of Steatotic Liver Disease: An Analysis of Data From a Prospective Cohort Study https://pubmed.ncbi.nlm.nih.gov/40945520/ (https://pubmed.ncbi.nlm.nih.gov/40945520/) The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test https://pubmed.ncbi.nlm.nih.gov/9738608/ (https://pubmed.ncbi.nlm.nih.gov/9738608/) Elevated ALT/AST Ratio as a Marker for NAFLD Risk and Severity: Insights From a Cross-Sectional Analysis in the United States https://pubmed.ncbi.nlm.nih.gov/39253584/ (https://pubmed.ncbi.nlm.nih.gov/39253584/) Alcohol Use Disorder: A Comparison Between DSM–IV and DSM–5 https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm (https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm) Wilson Disease https://emedicine.medscape.com/article/183456-overview (https://emedicine.medscape.com/article/183456-overview) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.

6. 

   25 Jun 2026

   Can Primary Care Catch MASLD Before Cirrhosis?

   MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat (https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 (https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1) The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review https://pubmed.ncbi.nlm.nih.gov/36626630/ (https://pubmed.ncbi.nlm.nih.gov/36626630/) AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/36727674/ (https://pubmed.ncbi.nlm.nih.gov/36727674/) Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41812830/ (https://pubmed.ncbi.nlm.nih.gov/41812830/) FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis (https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis) Noninvasive Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41640956/ (https://pubmed.ncbi.nlm.nih.gov/41640956/) NAFLD: Reporting Histologic Findings in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/33111374/ (https://pubmed.ncbi.nlm.nih.gov/33111374/) Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study https://pubmed.ncbi.nlm.nih.gov/37127100/ (https://pubmed.ncbi.nlm.nih.gov/37127100/) Cause-Specific Mortality in 13,099 Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease in Sweden https://pubmed.ncbi.nlm.nih.gov/40139508/ (https://pubmed.ncbi.nlm.nih.gov/40139508/) Liver Function Tests https://www.ncbi.nlm.nih.gov/books/NBK482489/ (https://www.ncbi.nlm.nih.gov/books/NBK482489/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.

Contact Medscape InDiscussion: MASLD

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.